IMCR Insider Trading

Insider Ownership Percentage: 10.40%
Insider Buying (Last 12 Months): $23,994,085.36
Insider Selling (Last 12 Months): $0.00

Immunocore Insider Trading History Chart

This chart shows the insider buying and selling history at Immunocore by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Immunocore Share Price & Price History

Current Price: $30.39
Price Change: Price Increase of +0.031 (0.10%)
As of 04/28/2025 10:30 AM ET

This chart shows the closing price history over time for IMCR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$30.16Closing price on 04/27/25:

Immunocore Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Immunocore (NASDAQ:IMCR)

84.50% of Immunocore stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMCR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.19Mbought$25ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Immunocore logo
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More on Immunocore

Today's Range

Now: $30.39
Low: $29.97
High: $31.03

50 Day Range

MA: $28.77
Low: $24.53
High: $30.81

52 Week Range

Now: $30.39
Low: $23.15
High: $62.74

Volume

251,246 shs

Average Volume

436,350 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Who are the company insiders with the largest holdings of Immunocore?

Immunocore's top insider shareholders include:
  1. Bros Advisors Lp Baker (Director)
  2. Leger Tina Amber St (Insider)
Learn More about top insider investors at Immunocore.

Who are the major institutional investors of Immunocore?

Immunocore's top institutional investors include:
  1. Hennion & Walsh Asset Management Inc. — 0.13%
  2. GAMMA Investing LLC — 0.04%
  3. Oppenheimer Asset Management Inc. — 0.02%
  4. Exchange Traded Concepts LLC — 0.01%
Learn More about top institutional investors of Immunocore stock.

Which major investors are selling Immunocore stock?

During the last quarter, IMCR stock was sold by these institutional investors:
  1. Exchange Traded Concepts LLC

Which major investors are buying Immunocore stock?

In the previous quarter, IMCR stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
  2. Hennion & Walsh Asset Management Inc.
  3. Oppenheimer Asset Management Inc.